about
Recent mortality from pleural mesothelioma, historical patterns of asbestos use, and adoption of bans: a global assessmentClinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusionsDistinct affinity of nuclear proteins to the surface of chrysotile and crocidoliteThe case for a global ban on asbestosAsbestos exposure predicts cell cycle control gene promoter methylation in pleural mesotheliomaGlobal magnitude of reported and unreported mesotheliomaDNA methylation profile of 28 potential marker loci in malignant mesotheliomaPleural plaques related to "take-home" exposure to asbestos: An international case seriesPerifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesotheliomaMalignant peritoneal mesothelioma.Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.The socioeconomic determinants of cancer.Improved Method for Analysis of Airborne Asbestos Fibers Using Phase Contrast Microscopy and FTIR Spectrometry.Environmental health survey in asbestos cement sheets manufacturing industry.Exercise training for asbestos-related and other dust-related respiratory diseases: a randomised controlled trialEstablishment of anti-mesothelioma monoclonal antibodiesTargeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenovirusesRanpirnase--an antitumour ribonuclease: its potential role in malignant mesothelioma.Worldwide trends in lung cancer pathology.Current concepts in malignant pleural mesothelioma.PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.Biomarkers for malignant pleural mesothelioma: current status.Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.Living with mesothelioma. A literature review.Asbestos-related pleuropulmonary diseases: benign and malignant.Estimation of personal exposure to asbestos of brake repair workers.Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.Downregulation of MUC1 expression and its recognition by CD8⁺ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi.Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma.Temporal trend, geographic distribution, and publication quality in asbestos research.Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project.New detoxification processes for asbestos fibers in the environment.Personal exposure to asbestos and respiratory health of heavy vehicle brake mechanics.Malignant mesothelioma: Canadian perspective and research directions.A dynamical model of the transport of asbestos fibres in the human body.Spatio-seasonal variation of airborne asbestos concentration in urban areas of Shiraz, Iran.Environmentally related diseases and the possibility of valuation of their social costs.Dusted community: piloting a virtual peer-to-peer support community for people with an asbestos-related diagnosis and their families.
P2860
Q23916445-94E9F8F0-78AB-4C68-8AF7-6474963276F0Q28238665-643DEF75-B23B-47DA-B154-899DB3210104Q28364944-BF14ABF6-2780-4A36-AE1A-01823D18081EQ28382786-F16BEE53-21DB-46AF-A505-86B4FA59EBA7Q28385230-A53D5938-7486-4904-8C61-F2BB1510CE06Q28388082-B85513B2-616F-466C-B256-7AB612B195F8Q28391214-CD4F49EB-110A-458A-ABE7-29DEEE394347Q28394326-A529F9C4-89A4-4D21-A34B-32AD41F814A9Q34271064-349D5497-F470-4A3E-87E6-61E33134BC23Q34390899-BC874ECD-14E5-4F38-A7BB-99337974351FQ34642678-E93394C3-67A0-4677-89B8-0D160129CB7EQ34775259-7DA31793-7F06-47D0-80C4-E72CD76AD1F0Q35112571-8974046D-DCDA-43BD-A26F-82E424E7F7D0Q35199710-C72B2222-E71E-4796-B6C4-8A73A0EEFE3AQ35434875-D63CA632-36BB-47D8-9242-D79A894CC862Q36061312-D7CFB2DD-A5DC-4F00-AAAE-1FEA1737DD59Q36387918-7B1CEA00-A5BF-473B-8C2F-8D14B9373390Q36425940-E2AAFDE9-7ADD-4B78-B7CB-68B4F168F7FFQ36568760-53700DFE-065F-4036-B190-102BA5425E3BQ37086026-94EB7BE7-2512-4C48-A194-E42BFF6656AAQ37293979-7B64DD07-90DC-469D-AF24-3CB288C842CCQ37335377-567F2456-F518-4051-B20D-E338DB1E651AQ37398672-7B6446C5-65C7-4692-8A78-304A6556FE20Q37615513-064C16D9-2B01-48D9-8DDD-624967AC4339Q38018217-CA9724DE-F20E-4BA1-AD97-0B830ADAB6D9Q39102541-60BAEF08-4659-434A-BA54-C5A351614D2CQ39129504-0730BE1B-C3E8-4237-AFD7-1999078AC9A6Q39432616-3B58B362-323D-4354-8586-2858BDDE77F2Q40336711-BD2D630C-9C13-4438-A60E-2E5B1AC1A5B3Q40341641-795EE634-0977-4800-9051-92105C218E5FQ41726870-6C0A7D1F-4A46-4C11-B60A-0F97129FF646Q41856729-CD7DB722-BB00-45A3-8F5E-EE8A3376FBB2Q42434574-C87707DF-992F-4AC8-A9BC-802411400A35Q43314193-0F560994-873F-44DE-B20D-5FC83DF6E555Q44214891-ADC568EC-8163-4932-936D-A717EFDD1A4AQ47098675-1AF0C6A4-437A-4851-B6F3-614D8418A4F6Q47741274-30511BD6-E795-482D-9376-CE129AB46807Q50109429-A7779057-6E0C-4FD2-BA4D-B9C365AC353AQ51774508-2A2DD851-7710-4AA7-AEEA-07FEA9FAF963Q51838655-EFF88590-5604-438A-8226-5750B3FEED22
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Asbestos and mesothelioma: worldwide trends.
@ast
Asbestos and mesothelioma: worldwide trends.
@en
type
label
Asbestos and mesothelioma: worldwide trends.
@ast
Asbestos and mesothelioma: worldwide trends.
@en
prefLabel
Asbestos and mesothelioma: worldwide trends.
@ast
Asbestos and mesothelioma: worldwide trends.
@en
P1433
P1476
Asbestos and mesothelioma: worldwide trends.
@en
P2093
Laurie Kazan-Allen
P356
10.1016/J.LUNGCAN.2005.03.002
P478
49 Suppl 1
P577
2005-04-20T00:00:00Z